Pharmacological Induction of Fetal Hemoglobin in β-Thalassemia and Sickle Cell Disease: An Updated Perspective

Simple item page
dc.contributor.authorBou-Fakhredin, Rayan
dc.contributor.authorDe Franceschi, L. De
dc.contributor.authorMotta, Irene
dc.contributor.authorCappellini, Maria Teresa
dc.contributor.authorTaher, Ali T.
dc.contributor.departmentInternal Medicine
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T11:43:47Z
dc.date.available2025-01-24T11:43:47Z
dc.date.issued2022
dc.description.abstractA significant amount of attention has recently been devoted to the mechanisms involved in hemoglobin (Hb) switching, as it has previously been established that the induction of fetal hemoglobin (HbF) production in significant amounts can reduce the severity of the clinical course in diseases such as β-thalassemia and sickle cell disease (SCD). While the induction of HbF using lentiviral and genome-editing strategies has been made possible, they present limitations. Meanwhile, progress in the use of pharmacologic agents for HbF induction and the identification of novel HbF-inducing strategies has been made possible as a result of a better understanding of γ-globin regulation. In this review, we will provide an update on all current pharmacological inducer agents of HbF in β-thalassemia and SCD in addition to the ongoing research into other novel, and potentially therapeutic, HbF-inducing agents. © 2022 by the authors. Licensee MDPI, Basel, Switzerland.
dc.identifier.doihttps://doi.org/10.3390/ph15060753
dc.identifier.eid2-s2.0-85132570952
dc.identifier.urihttp://hdl.handle.net/10938/30353
dc.language.isoen
dc.publisherMDPI
dc.relation.ispartofPharmaceuticals
dc.sourceScopus
dc.subjectFetal hemoglobin
dc.subjectGlobin gene
dc.subjectPharmacological induction
dc.subjectSickle cell disease
dc.subjectΒ-thalassemia
dc.subjectΓ-globin
dc.subject2 cyclohexyl n (1 isopropyl 4 piperidinyl) 6 methoxy 7 [3 (1 pyrrolidinyl)propoxy] 4 quinazolinamine
dc.subjectAciclovir
dc.subjectAzacitidine
dc.subjectBenserazide
dc.subjectCilostazol
dc.subjectDecitabine
dc.subjectDimethyl fumarate
dc.subjectDna methyltransferase inhibitor
dc.subjectHemoglobin f
dc.subjectHemoglobin gamma chain
dc.subjectHistone deacetylase inhibitor
dc.subjectHydroxyurea
dc.subjectMetformin
dc.subjectPomalidomide
dc.subjectSalubrinal
dc.subjectTenofovir disoproxil
dc.subjectTetrahydrouridine
dc.subjectThalidomide
dc.subjectTovinontrine
dc.subjectTranscription factor nrf2
dc.subjectTranylcypromine
dc.subjectVorinostat
dc.subjectBeta thalassemia
dc.subjectCarcinogenicity
dc.subjectCell differentiation
dc.subjectCell proliferation
dc.subjectCytotoxicity
dc.subjectDna methylation
dc.subjectDrug efficacy
dc.subjectDrug safety
dc.subjectErythroid precursor cell
dc.subjectErythropoiesis
dc.subjectGene editing
dc.subjectGene expression
dc.subjectHematopoietic stem cell
dc.subjectHemoglobinopathy
dc.subjectHuman
dc.subjectK-562 cell line
dc.subjectMorbidity
dc.subjectMortality
dc.subjectMultiple myeloma
dc.subjectParkinson disease
dc.subjectPharmacodynamics
dc.subjectPhenotype
dc.subjectPlatelet count
dc.subjectReview
dc.subjectRna interference
dc.subjectSickle cell anemia
dc.subjectSystematic review
dc.subjectThrombocytosis
dc.titlePharmacological Induction of Fetal Hemoglobin in β-Thalassemia and Sickle Cell Disease: An Updated Perspective
dc.typeReview

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
2022-5553.pdf
Size:
724.48 KB
Format:
Adobe Portable Document Format
Download

Collections

Internal Medicine